DKN 01

Drug Profile

DKN 01

Alternative Names: DKN-01; LY-2812176

Latest Information Update: 15 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Developer Leap Therapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action DKK1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Multiple myeloma
  • Phase I Biliary cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours

Most Recent Events

  • 08 Sep 2017 Leap Therapeutics and European Organisation for Research and Treatment of Cancer plan clinical trials of DKN 01 in combination with atezolizumab +/- paclitaxel in advanced Oesophagogastric malignancies and DKN 01 plus atezolizumab in advanced Biliary tract cancers across Europe in 2018
  • 11 Aug 2017 Leap Therapeutics plans a clinical trial for Gynaecological cancer in second half of 2017
  • 21 Jun 2017 Leap Therapeutics, in collaboration with Merck plans a phase II trial for Gastric cancer and Oesophageal cancer (Combination therapy, Late-stage disease, Second-line therapy) in second half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top